跳至主要内容
临床试验/NCT01014247
NCT01014247已完成1 期

A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial

Bayer0 个研究点目标入组 56 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Bayer
入组人数
56
主要终点
QTc interval at 3 hours

研究概览

简要总结

The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers
  • Age 18-75 years - Normal ECG

排除标准

  • Abnormal ECG - Intolerance to fluorochinolones

研究组 & 干预措施

Arm 1

Active Comparator

干预措施: Avelox (Moxifloxacin, BAY12-8039) (Drug)

Arm 2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

QTc interval at 3 hours

时间窗: Day 1 of treatment period 1 and 2

次要结局

  • Safety variables(Up to last visit of follow up)
  • Pharmacokinetic parameters(On different time points)

研究者

发起方
Bayer
申办方类型
Industry

相似试验

Influence of Moxifloxacin on QTc Interval in Healthy... | 临床试验